Chinese herbal medicine market continues to be weak. Prices of various herbal medicines are near freezing point

Business club, Aug 15 - high prices have been effectively curbed since May 2011, when the country set a watershed for structural adjustment, stable growth and stability through fine-tuning of economic policies The price of medicinal materials also retreated, from skyrocketing to stagnation and then to ebb Since May this year, the country has launched a special rectification of the adulteration of drugs and the order of operation in the pharmaceutical market, and successive adjustments and inspections have prevented the bubble economy caused by overheated investment In recent period, the price of many kinds of medicinal materials is close to the "freezing point" The price of Chinese medicinal materials in Bozhou trading hall, Anhui, the largest market of Chinese medicinal materials in China, is generally falling In addition to the increase of a few varieties of Panax notoginseng and Cordyceps sinensis, more than 80% of Chinese medicinal materials are falling, and the price of Atractylodes macrocephala is down by 70% The highest price of Atractylodes macrocephala is about 60-70 yuan / kg, which is only maintained at 20 yuan / kg at present It is estimated that new products will continue to decline in the market, about 15 yuan / kg Although Atractylodes macrocephala is easy to grow, it is not easy to store, so when the price falls, it must be sold immediately Looking back on the price changes of Atractylodes macrocephala in the past ten years, it shows obvious periodic fluctuations In 2005, it was about 14 yuan / kg, and in 2007, it went up to 56 yuan / kg, more than three times In 2008, it fell back to 13-14 yuan / kg In 2010, it rose to nearly 50 yuan / kg, nearly tripled, and then fell sharply all the way Now it has returned to the position of 18 yuan / kg, basically a roller coaster market Another kind of traditional Chinese medicine, Angelica dahurica, fluctuates more in price In the middle of 2009, it began to go up, up to about 17 yuan / kg at the beginning of 2011, which has been more than five times In the middle of 2011, it began to shake and sink, and now it's about 10 yuan / kg Coptis chinensis, Poria cocos, Gastrodia elata and Chrysanthemum indicum are important traditional Chinese medicine varieties in Hubei Province In 2009, the price of Coptis chinensis and poria cocos soared to 120 yuan / kg and 30 yuan / kg respectively The price of Gastrodia elata was once as high as 300 yuan / kg, and the price of Chrysanthemum indicum was over 20 yuan / kg At present, the prices of Coptis chinensis and poria cocos have dropped to 50 yuan / kg and 15 yuan / kg respectively, shrinking by more than 50%, Gastrodia elata to 18 yuan / kg, chrysanthemum indicum to 12 yuan / kg When the price of traditional Chinese medicine rises, it is absolutely worthy of being the "leader" Since 2009, the price of Radix Pseudostellariae has increased more than ten times from about 30 yuan / kg, and its price once reached 600 yuan / kg, which made the purchasers flinch Not only did it disappear in the hospital pharmacy, but also the Jiangzhong pharmaceutical industry, which used Radix Pseudostellariae as an important raw material to produce Jianwei Xiaoshi tablets, also heard the news of production restriction Now, the price of Pseudostellaria has fallen all the way to about 180 yuan / kg In addition, Ligusticum chuanxiong, whose price directly increased from 10 yuan / kg to the highest point of 35 yuan / kg, and Ophiopogon japonicus, whose price once increased from 40 yuan / kg to 150 yuan / kg, were all returned to "original" this year At present, the price of Ligusticum chuanxiong in the market of traditional Chinese medicine is about 10 yuan / kg, while that of Ophiopogon japonicus is about 35 yuan / kg The main reason for the sharp fluctuation of the prices of these agricultural products is that the unbearable weight has gone up and down The main channel for the digestion of traditional Chinese medicine belongs to pharmaceutical enterprises However, from the perspective of the export of the pharmaceutical Canton Fair in May this year, the transaction amount of products in several categories, such as traditional Chinese medicine extract, traditional Chinese medicine and Chinese patent medicine, has declined to varying degrees compared with the previous one At the same time, domestic production has also been greatly reduced, and the plight of pharmaceutical companies has a great impact on the continued weakness of the Chinese herbal medicine market, mainly due to the following aspects: First, due to the deterioration of debt crisis in Europe and the United States this year, the economic growth rate has dropped significantly The international relations between China and some countries are tense The export of medicine market has repeatedly shown policy barriers, and the shortage of foreign demand is relatively prominent The export of extracts and medicinal materials has declined significantly At present, the change of exchange rate also damages the interests of export enterprises Therefore, some foreign processing pharmaceutical enterprises reduce the purchase of raw materials Second, with the sharp increase of labor force and production cost of raw materials, the profits of enterprises have declined Due to the slow return of funds from downstream enterprises, the limited funds of pharmaceutical enterprises are more limited In order to exchange for capital flow, pharmaceutical enterprises have to reduce the stock of raw materials and medicines Third, when the price of raw materials and medicinal materials fell, the medical reform and medicine were promoted separately In order to eliminate the unreasonable drug price, the state lowered the price of basic medicine for medical insurance, and pharmaceutical enterprises also appropriately reduced production and raw material purchase Fourth, with the rectification of the market, we will severely crack down on fake and inferior drugs adulterated and produced, so that drug companies can reduce the proportion of product inventory, so as to avoid the occurrence of bad conditions in the inspection and increase the cost of punishment Summer is the best time to repair the machine, so most pharmaceutical companies only guarantee the supply of baseline inventory, reduce the backlog of medicine and products To sum up, with the rising cost of pharmaceutical enterprises and the continuous increase of business pressure, domestic low-end pharmaceutical enterprises are facing increasingly fierce competition and upgrading of pharmaceutical industry, and the overall purchasing power is obviously insufficient When the market and the origin of the stock of medicinal materials are not well digested, the market transaction is weak, and the price decline will continue In the early stage, the recovery of cultivated medicinal materials stimulated by high prices will usher in new production from this year to next year At present, the slight increase in the prices of some medicinal materials will not play a role in boosting the overall pharmaceutical market, and the future market is not optimistic.